Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
From Avacta LFT page on their site:
'*Clinical evaluation study conducted at Hospital Carlos III and Hospital Universitario La Paz, Madrid, Spain between March-April 2021 using samples from patients with a recently confirmed SARS-CoV-2 RT-qPCR test result, from a variety of settings including hospital in-patients, walk-in test centres and participants in epidemiological studies.'
Dr Pablo Castan, Hospital Carlos III, Madrid.
If this chap has such close links to Medusa, is it not giving anyone else marking your own homework vibes?
In my opinion IFA its good because it continues the tradition whereby there is no other mainstream testing company more transparent or informative than AVACTA as regards the method of validating their test and the way that the tests performance is calculated.
If anyone disagrees feel free to name a rival.
Why is this at all good? Stinks of back door.
Hi Walsheeey All research very welcome keep posting .
*there
Not at all - their might be something in it. Always worth a post. Thanks.
Ah no worries. My bad. Definitely didn't read through that properly before posting :). Though still interests me that Mirnax has ties to M19 at least.
Dr Pablo Castan : Think was involved in creating the Medusa 19 Rapid Saliva Protein Test .
"19.01.2021 By Medusa19
This morning the Castilla La Mancha regional television channel in Spain, interviewed Dr. Pablo Castán from the La Paz Hospital in Madrid, to explain what the Medusa 19 Rapid Saliva Protein Test consists of, the test has been developed in a coordination with Medusa 19 and the Carlos III Hospital/Instituto Carlos III, La Paz Hospital in Madrid."
Welcome mate. Looks neat.
"Evaluation in the Public Universities of the Community of Madrid of a new rapid test for the detection in saliva of the IMMUNE RESPONSE to contact with SARS-CoV-2"
This is referring to their protein antibody test, I assume?
Hi all,
First post here. Do go easy.. I normally just lurk, but a couple of things caught my interest today. It May be absolutely nothing, but equally, if it is "something" hopefully some of the better researchers on here can look into it better than I...
So looking at the update on the website with the 11 samples clinical validation.. The CV was signed of by Dr Pablo Castan in Madrid. Looking in to the name, I couldn't locate a Pablo Castan in Madrid.. However, did find a Pablo Castan - Chief Scientific Officer at Mirnax Biosense in Manchester: Profile below:
https://www.linkedin.com/in/pablo-castan-2b19b374/
Then I started looking in to Mirnax Biosense as couldn't find any further Dr Pablo Castans with any Scientific qualifications in a relevant field.
Looking through the Mirnax Biosense employees, I stumbled across their Scientific Director - Anabel Gil Garcia.
https://www.linkedin.com/in/anabel-gil-garc%C3%ADa-b1b588211/
She has been at Mirnax Biosense for 3 years. What really interested me though was the project she was working on in 2020 on behalf of Mirnax (as far as I can see)
Research technical manager
Company NameMedusa19
Dates EmployedOct 2020 – Nov 2020
Employment Duration2 mos
LocationMadrid, Community of Madrid, Spain
Clinical study at the Autonomous University of Madrid.
"Evaluation in the Public Universities of the Community of Madrid of a new rapid test for the detection in saliva of the immune response to contact with SARS-CoV-2".
So we have a company who have a CSO with the same name as the one signing off the AVCT CV, who had previously conducted work on the Medusa19 Covid test (which we know to be Avacta).
Is it entirely possible that this is all interlinked and Medusa19 are also involved in Spain, or further afield? It seems to point that way.
Dr Pablo Castan is now located in Manchester. Any odds his place of work is the Medusa19 building?
As I said, I'm not trying to be rampy, before anyone calls that out, but there seems to be a lot of circumstantial evidence pointing towards a lot going on in the continent on M19's behalf.
If any of the more seasoned researchers could pick this up and run with it, that would be awesome. Again, I may well be putting 2 and 2 together and getting 35... But thought it worth a post :)